Skip to content

Briagen Observational Study

Briagen™ Case Study and Observation of Skin Excision Healing in Mohs and Other Dermatological Procedures

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04090970
Acronym
BOS
Enrollment
30
Registered
2019-09-16
Start date
2019-08-26
Completion date
2020-05-31
Last updated
2019-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mohs Surgery

Brief summary

This research study is evaluating a study product called Briagen™ as a possible treatment for wound healing after Mohs procedure.

Detailed description

Briagen, the study product being used in this study, is a natural complex carbohydrate wound dressing for skin wounds created by Mohs surgery. Briagen was developed with the intent to improve healing time and reduce scarring of skin wounds. Briagen seeks to match the mechanical aspects of your skin (thickness, stiffness, hydration, pore size) to assist in the healing process. The purpose of this research study is to observe healing time of Briagen applied to wounds created as a result of Mohs surgery.

Interventions

DEVICEBriagen

Natural complex carbohydrate wound dressing for skin wounds

Sponsors

Gemstone Biotherapeutics
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Patient seeking treatment for wound created by Mohs or other full thickness skin excisions 2. Over 18 years of age 3. English-speaking 4. Presents for treatment within 24 hours of initial Mohs skin excision procedure.

Exclusion criteria

1. History of significant wound complications and non-compliance on wound maintenance instructions (infections, disturbing the wound during the healing process, etc.) 2. Known diagnosis of Diabetes 3. Active infection in the wound bed 4. Under 18 years of age

Design outcomes

Primary

MeasureTime frame
Healing Time28 days

Countries

United States

Contacts

Primary ContactEmily English, PhD
info@gemstonebio.com443-682-7740

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026